Corneal Crosslinking for Treatment of Corneal Neovascularization
Randomized Comparison of Standard vs. Accelerated Corneal Crosslinking for Treatment of Corneal Neovascularization With or Without Concomitant Inflammation and/or Infection
Price Vision Group
62 participants
May 3, 2021
INTERVENTIONAL
Conditions
Summary
The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
Eligibility
Inclusion Criteria3
- years of age or older
- With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.
- Signed written informed consent.
Exclusion Criteria3
- Known sensitivity to treatment medications
- Current condition that in the investigator's opinion could compromise safety or data integrity.
- Pregnancy (including plan to become pregnant) or lactation during the course of the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes
Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04787471